Axsome Therapeutics
AXSM
AXSM
189 hedge funds and large institutions have $1.15B invested in Axsome Therapeutics in 2022 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 69 increasing their positions, 48 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
9% more funds holding
Funds holding: 174 → 189 (+15)
8.26% more ownership
Funds ownership: 55.5% → 63.76% (+8.3%)
0% more call options, than puts
Call options by funds: $114M | Put options by funds: $113M
Holders
189
Holding in Top 10
5
Calls
$114M
Puts
$113M
Top Buyers
| 1 | +$76.9M | |
| 2 | +$47.7M | |
| 3 | +$28.8M | |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$26M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.5M |
Top Sellers
| 1 | -$31.7M | |
| 2 | -$16M | |
| 3 | -$13.5M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.85M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$7.64M |